These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 28408749)
1. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749 [TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233 [TBL] [Abstract][Full Text] [Related]
3. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. Dardis C; Donner D; Sanai N; Xiu J; Mittal S; Michelhaugh SK; Pandey M; Kesari S; Heimberger AB; Gatalica Z; Korn MW; Sumrall AL; Phuphanich S BMC Neurol; 2021 Jun; 21(1):231. PubMed ID: 34162346 [TBL] [Abstract][Full Text] [Related]
4. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773 [TBL] [Abstract][Full Text] [Related]
6. Gliosarcoma with PNET features mimicking a metastatic neuroendocrine carcinoma: A diagnostic dilemma. McGahan BG; Toop N; Ward S; Jones D; Kobalka PJ; Palmer JD; Elder JB Clin Neuropathol; 2021; 40(5):279-285. PubMed ID: 34190681 [TBL] [Abstract][Full Text] [Related]
7. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
8. Gliosarcoma with osteosarcomatous component: A case report and short review illustration. Chen Y; Zhou S; Zhou X; Dai X; Wang L; Chen P; Zhao S; Shi C; Xiao S; Dong J Pathol Res Pract; 2022 Apr; 232():153837. PubMed ID: 35278815 [TBL] [Abstract][Full Text] [Related]
9. Gliosarcomas with the Wang L; Sun J; Li Z; Chen L; Fu Y; Zhao L; Liu L; Wei Y; Teng L; Lu D J Clin Pathol; 2017 Dec; 70(12):1079-1083. PubMed ID: 28775171 [TBL] [Abstract][Full Text] [Related]
10. Genetic alteration and clonal evolution of primary glioblastoma into secondary gliosarcoma. Li J; Zhao YH; Tian SF; Xu CS; Cai YX; Li K; Cheng YB; Wang ZF; Li ZQ CNS Neurosci Ther; 2021 Dec; 27(12):1483-1492. PubMed ID: 34605602 [TBL] [Abstract][Full Text] [Related]
11. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior. Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Actor B; Cobbers JM; Büschges R; Wolter M; Knobbe CB; Lichter P; Reifenberger G; Weber RG Genes Chromosomes Cancer; 2002 Aug; 34(4):416-27. PubMed ID: 12112531 [TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897 [TBL] [Abstract][Full Text] [Related]
14. Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. Lowder L; Hauenstein J; Woods A; Chen HR; Rupji M; Kowalski J; Olson JJ; Saxe D; Schniederjan M; Neill S; Weinberg B; Sengupta S J Neurooncol; 2019 Jul; 143(3):381-392. PubMed ID: 31073965 [TBL] [Abstract][Full Text] [Related]
15. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
16. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075 [TBL] [Abstract][Full Text] [Related]
17. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations. Cheng CD; Chen C; Wang L; Dong YF; Yang Y; Chen YN; Niu WX; Wang WC; Liu QS; Niu CS Anal Cell Pathol (Amst); 2022; 2022():2376288. PubMed ID: 35757013 [TBL] [Abstract][Full Text] [Related]
18. Treatment-associated Pain M; Wang H; Lee E; Strahl M; Hamou W; Sebra R; Zhu J; Yong RL Oncotarget; 2018 Jan; 9(2):2603-2621. PubMed ID: 29416795 [TBL] [Abstract][Full Text] [Related]
19. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608 [TBL] [Abstract][Full Text] [Related]
20. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Rodriguez FJ; Scheithauer BW; Giannini C; Bryant SC; Jenkins RB Cancer; 2008 Nov; 113(10):2779-89. PubMed ID: 18816605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]